Want to join the conversation?
R&D expense for 3Q15 was $174.8MM, up $16.6MM YoverY. R&D increased primarily due to the impact of the acquired EPD business, which raised R&D by approx. $17MM in the current quarter. Additionally, R&D increased due to the continued development of $MYL respiratory, insulin and biologics programs, partially offset by lower expense on other programs.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.